ABBYY Accelerates U.S. Food and Drug Administration’s Public Health Initiatives

MILPITAS, Calif.–(BUSINESS WIRE)–#DigitalIntelligenceABBYY announced today that the U.S. Food and Drug Administration (FDA) is using its Digital Intelligence platform to accelerate its public health initiatives. ABBYY solutions digitize and process data within documents used for monitoring public health, including the government agency’s 30-year archive of forms used to report adverse events and current documents to ensure that critical reporting is captured accurately and quickly.

“Going forward, we plan to use ABBYY to process newly received health reports and utilize the data in our downstream enterprise workflow and visualization software,” stated Justin Scott, Senior Business Informatics Officer, Office of Business Informatics, U.S. FDA. “ABBYY has brought us into the 21st century.”

ABBYY’s Digital Intelligence platform accelerates digital transformation and complements organizations’ existing intelligent automation platforms like RPA, BPM, ERP, ECM, EHR, and others. ABBYY brings together the best NLP, machine learning, and advanced recognition capabilities into a single, enterprise-scale platform to handle every type of document, from simple forms to complex free-form documents whether in electronic, paper and PDF formats. ABBYY enables the FDA to process thousands of pages per day containing over two dozen versions of forms with upwards of 120 complex fields with 99%+ accuracy.

“Government agencies like the FDA realize that automation starts with a comprehensive platform for acquiring, processing, validating and delivering the right data into critical processes,” commented Bruce Orcutt, SVP of Product Marketing at ABBYY. “We are helping the FDA capture and extract vital data from complex health documents and ensure they are delivered to the appropriate parties. Having this real-time access to information is the cornerstone to having comprehensive digital intelligence into how their business is operating and fuel more positive outcomes for constituents.”

Digital Intelligence means gaining the valuable, yet often hard to attain, insight into your operations that enables true business transformation. With access to real-time data about exactly how your processes are currently working and the content that fuels them, Digital Intelligence empowers organizations to make tremendous impact where it matters most: customer experience, competitive advantage, visibility, and compliance.

To learn more about ABBYY’s full suite of Digital Intelligence solutions to transform processes and content, please visit: https://www.abbyy.com/solutions/digital-intelligence/.

About the U.S Food and Drug Administration

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of the nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

About ABBYY

ABBYY empowers organizations to gain a complete understanding of their business processes and the content that fuels them with its Digital Intelligence platform. ABBYY technologies are used by more than 5,000 companies, including many of the Fortune 500, and is recognized for its leadership in Intelligent Document Processing (IDP) and Process Discovery & Mining for driving significant impact where it matters most: customer experience, effectiveness, profitability and competitive advantage. ABBYY is a global company with offices in 13 countries. For more information, visit www.abbyy.com/company.

ABBYY and the ABBYY Logo are either registered trademarks or trademarks of ABBYY Software Ltd. Other product names mentioned herein may be trademarks and/or registered trademarks of their respective owners and are hereby recognized.

Contacts

ABBYY Media Contact

Gina Ray, APR

gina.ray@abbyy.com
(949) 370-0941

Staff

Recent Posts

Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

20 minutes ago

Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin

Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…

20 minutes ago

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

1 hour ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

2 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

2 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

2 hours ago